A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation

ABSTRACT In a retrospective single centre study we examined the outcome of five different therapy approaches in 48 patients in whom a relapse of CML (13 cytogenetic relapses, 35

hematological relapses: 10 chronic phase (CP), nine accelerated phase, 16 blast crisis) occurred after allogeneic BMT. Cyclosporin A (CsA) withdrawal, interferon alpha-2b (IFN-_α_) therapy,

donor leukocyte transfusions (DLT), second transplantation (2nd BMT), and chemotherapy (CTX) alone were used and studied for their response rates. Patients who achieved a complete

hematologic and cytogenetic remission (CR) were studied for BCR-ABL transcripts and for their chimerism status by PCR. A strong antileukemic effect was observed after abrupt CsA withdrawal,

with 10 of 20 patients achieving a CR (50%). All 10 patients with early stage (nine cytogenetic and one CP), but none of the patients with advanced disease recurrence, responded to CsA

withdrawal. IFN-_α_induced in five of 11 patients (45%) a stable cytogenetic remission, whereas treatment with DLT induced a CR in only two of 14 patients (14%). A second transplant was

performed in six patients. Three of six patients (50%) survive disease-free at a median of 19 months after the 2nd BMT (range 10–25). The use of CTX alone did not induce a remission. Access

through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal

Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices

may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support

SIMILAR CONTENT BEING VIEWED BY OTHERS IMPACT OF DONOR-DERIVED CD34 + INFUSED CELL DOSE ON OUTCOMES OF PATIENTS UNDERGOING ALLO-HCT FOLLOWING REDUCED INTENSITY REGIMEN FOR MYELOFIBROSIS: A

STUDY FROM THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT Article 01 December 2021 ALLOGENEIC BLOOD OR MARROW TRANSPLANTATION WITH HAPLOIDENTICAL DONOR AND POST-TRANSPLANTATION

CYCLOPHOSPHAMIDE IN PATIENTS WITH MYELOFIBROSIS: A MULTICENTER STUDY Article 18 October 2021 COMPARABLE OUTCOMES OF HAPLOIDENTICAL TRANSPLANT WITH TBF CONDITIONING VERSUS MATCHED UNRELATED

DONOR WITH FLUDARABINE/BUSULFAN CONDITIONING FOR ACUTE MYELOID LEUKEMIA Article 06 October 2020 AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Bone Marrow Transplantation,

University Hospital of Essen, Essen, Germany AH Elmaagacli, DW Beelen & UW Schaefer Authors * AH Elmaagacli View author publications You can also search for this author inPubMed Google

Scholar * DW Beelen View author publications You can also search for this author inPubMed Google Scholar * UW Schaefer View author publications You can also search for this author inPubMed 

Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Elmaagacli, A., Beelen, D. & Schaefer, U. A retrospective single centre study of the

outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. _Bone Marrow Transplant_ 20, 1045–1055

(1997). https://doi.org/10.1038/sj.bmt.1701026 Download citation * Received: 03 April 1997 * Accepted: 30 June 1997 * Issue Date: 01 December 1997 * DOI:

https://doi.org/10.1038/sj.bmt.1701026 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * CML * relapse * interferon * cyclosporine * BMT